Metabolic Effects of Furosemide +HSS in Refractory Ascites
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Introduction: Patients with chronic liver diseases are usually thin as a result of
hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of
other adyponectins such as visfatin.
Aims: To evaluate the metabolic and inflammatory effects of intravenous high-dose furosemide
plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard
oral diuretic schedule, in patients with cirrhosis and refractory ascites.
Methods; All consecutive cirrhotic patients with refractory ascites unresponsive to
outpatient treatment will be enrolled . Enrolled subjects will be randomized to treatment
with intravenous infusion of furosemide (125-250mg⁄bid) plus small volumes of HSS from the
first day after admission until 3 days before discharge (Group A ), or repeated paracentesis
from the first day after admission until 3 days before discharge (Group B, ).
Plasma levels of ANP, BNP, Leptin, visfatin, IL-1β, TNF-a, IL-6 were measured before and
after the two type of treatment.